## Clinical Scenario Interpretation The patient has **borderline tuberculoid (BT) leprosy** with: - Good clinical response to MDT (lesion flattening, sensory recovery) - **Low bacillary load** (1+ AFB) - **Acute inflammation of existing lesions** (not new nodules) - **Neuritis and iritis** (extracutaneous involvement) - **8 months into treatment** (well-established timing for reversal reaction) These features are classic for **Type 1 lepra reaction (Reversal Reaction)**, not Type 2. ## Type 1 Lepra Reaction (Reversal Reaction) **Key Point:** Type 1 lepra reaction is a **delayed-type hypersensitivity (Type IV) response** to *Mycobacterium leprae* antigens that occurs in **borderline forms of leprosy** (BT, BL, BB). It reflects immune reconstitution as the patient's cell-mediated immunity improves during MDT. ### Pathophysiology 1. **Antigen release:** Rifampicin rapidly kills bacteria, releasing mycobacterial antigens 2. **Immune response:** Patient's recovering T-cell immunity (CD4+ and CD8+ cells) recognizes *M. leprae* antigens 3. **DTH reaction:** Granulomatous inflammation in skin and nerves 4. **Timing:** Usually 1–12 months after starting MDT (can occur before or after completion) ### Clinical Features of Type 1 Reaction - **Skin:** Inflammation of **existing lesions** (edema, erythema, induration) - **Nerves:** Acute neuritis, nerve tenderness, sensory/motor loss - **Eyes:** Iritis, anterior uveitis - **Systemic:** Minimal fever; constitutional symptoms absent - **Bacillary load:** Low (BT, BB) to moderate (BL) **High-Yield:** Type 1 reaction is a sign of **immune recovery**, not treatment failure. It occurs in borderline cases and is managed with corticosteroids while continuing MDT. ### Role of Rifampicin Rifampicin is the most potent antileprotic drug and causes rapid bacterial death. The massive release of mycobacterial antigens (especially cell wall lipids and proteins) triggers the Type IV hypersensitivity response in patients with recovering cell-mediated immunity. ## Comparison: Type 1 vs. Type 2 Lepra Reactions | Feature | Type 1 (Reversal) | Type 2 (ENL) | |---------|-------------------|---------------| | **Hypersensitivity type** | Type IV (DTH) | Type III (Immune complex) | | **Leprosy classification** | Borderline (BT, BL, BB) | LL, BL | | **Bacillary load** | Low to moderate | High (3–4+) | | **Lesion pattern** | Existing lesions inflame | New painful nodules | | **Systemic symptoms** | Minimal | Fever, malaise | | **Timing** | 1–12 months after MDT | Weeks to years | | **Neuritis/Iritis** | Common | Common | | **Management** | Corticosteroids | Corticosteroids + thalidomide | | **Trigger** | Rifampicin-induced antigen release | Immune complex deposition | **Clinical Pearl:** A borderline leprosy patient with low bacillary load who develops acute lesion inflammation and neuritis during MDT has Type 1 reaction until proven otherwise. ## Why Not the Other Options? **Clofazimine:** While clofazimine can cause phototoxic dermatitis (blue-black discoloration, photosensitivity), this is a **direct drug effect**, not an immune reaction. It does not cause acute inflammation of existing lesions or neuritis. **Dapsone:** Dapsone is a sulfonamide and can cause hemolytic anemia, methemoglobinemia, and rarely severe cutaneous reactions (SJS/TEN), but it is **not** the primary trigger of Type 1 lepra reaction. Rifampicin's rapid bactericidal action is the key driver. ## Management of Type 1 Lepra Reaction 1. **Continue MDT** — essential; do not stop antileprotic drugs 2. **Corticosteroids** — prednisolone 0.5–1 mg/kg/day, taper over 8–12 weeks 3. **NSAIDs** — for mild cases 4. **Protect nerves** — immobilization, physiotherapy to prevent contractures 5. **Monitor vision** — ophthalmology review for iritis [cite:KD Tripathi 8e Ch 47; Harrison 21e Ch 203]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.